Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06936735 | A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 502 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07197554 | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 171 | SEED Therapeutics, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05039801 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors |
| recruiting |
| Phase 1 |
| 54 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jun 1, 2026 |
| clinicaltrials |
| NCT07618260 | SIM0613 in Participants With Advanced Solid Tumors(SIM0613-101) | recruiting | Phase 1 | 294 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04145622 | Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | recruiting | Phase 1 / Phase 2 | 250 | Daiichi SankyoINDUSTRY | 2 | May 29, 2026 | clinicaltrials |
| NCT06533332 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | EtiraRx Australia Pty LtdOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 201 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07404332 | 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | recruiting | Phase 1 | 35 | Mohammed MilhemOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07538479 | Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)(NIVALIS) | recruiting | Phase 1 | 24 | West China HospitalOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements(TRIDENT-1) | recruiting | Phase 1 / Phase 2 | 500 | Turning Point Therapeutics, Inc.INDUSTRY | 19 | May 27, 2026 | clinicaltrials |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | recruiting | Phase 1 / Phase 2 | 840 | Nuvalent Inc.INDUSTRY | 15 | May 27, 2026 | clinicaltrials |
| NCT05599048 | Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 65 | Robert Bok, MD, PhDOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05277168 | A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | recruiting | Phase 1 / Phase 2 | 83 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 4 | May 22, 2026 | clinicaltrials |
| NCT06386146 | JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | recruiting | Phase 1 / Phase 2 | 144 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT06656390 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 202 | Shanghai Allink Biotherapeutics Co., Ltd.INDUSTRY | 3 | May 22, 2026 | clinicaltrials |
| NCT06977737 | A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours(ATTEST) | recruiting | Phase 1 / Phase 2 | 72 | Accession Therapeutics LimitedINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT06006273 | A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors | recruiting | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 64 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07596693 | KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma) | recruiting | Phase 1 | 30 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT07459998 | SKB103 for Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 277 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT05329103 | A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 65 | Peel Therapeutics IncINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06066424 | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589530 | Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors(SOLID-NK) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06739291 | A Study of SIGX1094R in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 102 | Signet TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT03686124 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors(ACTengine) | recruiting | Phase 1 / Phase 2 | 375 | Immatics US, Inc.INDUSTRY | 2 | May 13, 2026 | clinicaltrials |
| NCT05036226 | COAST Therapy in Advanced Solid Tumors and Prostate Cancer(COAST) | recruiting | Phase 1 / Phase 2 | 76 | Medical University of South CarolinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06223542 | Studying TAK-243 in Patients With Advanced Cancer | recruiting | Phase 1 | 95 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06474455 | A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT07563972 | Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05367635 | A Study of SKB315 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 246 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05954312 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 290 | Vividion Therapeutics, Inc.INDUSTRY | 3 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06428331 | A Study of SKB518 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 150 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06725758 | A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours(TEADES) | recruiting | Phase 1 / Phase 2 | 315 | Orion Corporation, Orion PharmaINDUSTRY | 6 | May 8, 2026 | clinicaltrials |
| NCT06736327 | A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 180 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06826040 | SKB445 for Injection in Solid Tumors | recruiting | Phase 1 | 126 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07087197 | A Study of SKB107 in Advanced Solid Tumors With Bone Metastases | recruiting | Phase 1 | 90 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07380386 | SKB105 for Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 256 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06726369 | A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 90 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT06819735 | Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors(DOMISOL) | recruiting | Phase 1 / Phase 2 | 125 | Domain Therapeutics Australia Pty LtdINDUSTRY | 3 | May 6, 2026 | clinicaltrials |
| NCT06214143 | A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 68 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04511039 | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | recruiting | Phase 1 | 45 | Roswell Park Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06132503 | Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors | recruiting | Phase 1 | 110 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06349837 | Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors | recruiting | Phase 1 | 24 | Sichuan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 2, 2026source: clinicaltrials